Verrica Pharmaceuticals Inc (NASDAQ: VRCA) kicked off on Friday, down -3.69% from the previous trading day, before settling in for the closing price of $2.44. Over the past 52 weeks, VRCA has traded in a range of $2.02-$11.41.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -13.60%. While this was happening, its average annual earnings per share was recorded -1.80%. With a float of $25.98 million, this company’s outstanding shares have now reached $42.41 million.
Considering the fact that the conglomerate employs 100 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 84.14%, operating margin of -563.14%, and the pretax margin is -625.06%.
Verrica Pharmaceuticals Inc (VRCA) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Verrica Pharmaceuticals Inc is 39.28%, while institutional ownership is 43.77%. The most recent insider transaction that took place on Aug 26 ’24, was worth 69,647. In this transaction CHIEF LEGAL OFFICER of this company sold 26,183 shares at a rate of $2.66, taking the stock ownership to the 115,303 shares. Before that another transaction happened on Aug 27 ’24, when Company’s CHIEF LEGAL OFFICER sold 9,530 for $2.46, making the entire transaction worth $23,444. This insider now owns 105,773 shares in total.
Verrica Pharmaceuticals Inc (VRCA) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -1.80% per share during the next fiscal year.
Verrica Pharmaceuticals Inc (NASDAQ: VRCA) Trading Performance Indicators
Take a look at Verrica Pharmaceuticals Inc’s (VRCA) current performance indicators. Last quarter, stock had a quick ratio of 2.23. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.21.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.88, a number that is poised to hit -0.38 in the next quarter and is forecasted to reach -0.98 in one year’s time.
Technical Analysis of Verrica Pharmaceuticals Inc (VRCA)
Compared to the last year’s volume of 0.34 million, its volume of 2.12 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 25.34%. Additionally, its Average True Range was 0.46.
During the past 100 days, Verrica Pharmaceuticals Inc’s (VRCA) raw stochastic average was set at 3.51%, which indicates a significant decrease from 8.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 215.03% in the past 14 days, which was higher than the 108.88% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.88, while its 200-day Moving Average is $6.08. Nevertheless, the first resistance level for the watch stands at $2.47 in the near term. At $2.59, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.68. If the price goes on to break the first support level at $2.25, it is likely to go to the next support level at $2.16. Should the price break the second support level, the third support level stands at $2.04.
Verrica Pharmaceuticals Inc (NASDAQ: VRCA) Key Stats
The company with the Market Capitalisation of 100.27 million has total of 42,420K Shares Outstanding. Its annual sales at the moment are 5,120 K in contrast with the sum of -67,000 K annual income. Company’s last quarter sales were recorded 5,180 K and last quarter income was -17,190 K.
